Robert E. Reiter, MD, presented “PSMA Imaging as a Biomarker for Early Stage Prostate Cancer” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Reiter, Robert E. “PSMA Imaging as a Biomarker for Early Stage Prostate Cancer.” August 2024. Accessed Oct 2026. https://grandroundsinurology.com/psma-imaging-as-a-biomarker-for-early-stage-prostate-cancer/
PSMA Imaging as a Biomarker for Early Stage Prostate Cancer – Summary
Robert E. Reiter, MD, discusses PSMA imaging’s potential as a biomarker for early-stage prostate cancer. In this 11-minute presentation, Dr. Reiter compares PSMA PET and MRI. PSMA PET imaging, more sensitive than MRI, can detect cancer presence, tumor size, and potential spread beyond MRI’s capability, offering a possible advantage in early and focal disease management.
PSMA’s prognostic value is explored. Data indicate a correlation between high PSMA uptake (SUV) and higher Gleason scores. Low PSMA expression is linked with more aggressive cancer markers.
Additionally, Dr. Reiter asserts that PSMA’s potential as a guide in surgical procedures, such as radio-guided lymph node removal, could enhance surgical precision and reduce the chance of residual disease.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Robert E. Reiter, MD, MBA, is the Bing Professor of Urologic Oncology and a Professor of Molecular Biology at the University of California, Los Angeles, Los Angeles, California. Dr. Reiter also serves as the Director of the Prostate Cancer Program and of Urologic Research, as Chief of the Division of Urologic Oncology, and as Co-Director of the Genitourinary Oncology Program for the Jonsson Cancer Center at the University of California, Los Angeles. He is an internationally recognized expert in all areas of prostate cancer management and research. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans.
